Of patients with a BRCA mutation , median PFS was significantly longer in the olaparib group than in the placebo group ( @ months -LSB- @ % CI @-not calculable -RSB- vs @ months -LSB- @-@ -RSB- ; HR @ -LSB- @-@ -RSB- ; p < @ ) ; similar findings were noted for patients with wild-type BRCA , although the difference between groups was lower ( @ months -LSB- @-@ -RSB- vs @ months -LSB- @-@ -RSB- ; HR @ -LSB- @-@ -RSB- ; p = @ ) .